undamentalytics Newsletter
Sign in

Schrodinger, Inc. (SDGR) stock

Add to watchlist

Add holding +

NASDAQ: SDGR Nasdaq Life Sciences Tools & Services Next results ~November 4, 2026

C Fundamentals grade

Schrodinger, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$9.7

Forward price-to-sales vs peers

Base case. Range ~$7.9–$20. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Schrodinger, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 7 selling0 purchases and 20 sales by directors and officers, last 12 monthsInsider trades
  • Funds125 adding, 100 cuttingOf 42 active managers that changed their stake, 19 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Schrodinger files

Where Schrodinger stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $259m, up 8.9% on a year earlier, slower than the 10.6% growth a quarter earlier. Free-cash-flow margin fell to -50.3% from 10.2% a year earlier. Operating margin widened to -59.2% from -81.1%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $1.49 a share, against a share price of $30.48.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Schrodinger, Inc.'s trailing-twelve-month revenue grew 8.9% year on year, with a free-cash-flow margin of -50.3%. Where it stands out: days sales outstanding of 30 days ranks 6 of 48 life sciences tools & services companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 8.9% (-1.7pp vs the prior quarter), the 3rd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 21.9 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.3bn.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -59.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -50.3% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 66% and a beta of 1.8 against the S&P 500.
  • Below peers: stock pay as % of revenue. Stock pay as % of revenue of 14.9% ranks 41 of 53 life sciences tools & services companies we cover (median 4.4%).
  • Heavily shorted. 24.8% of the shares available to trade are sold short (3.2 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.42 against an average estimate of -$0.67: beat by 37.9%
Revenue
$59m, up 7.5% on a year earlier
Share reaction
+13.8% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 4, 2026

Schrodinger's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.5%
  • 1 week+6.9%
  • 1 month-13.6%
  • This year+46.5%
  • 1 year+24.5%
  • 5 years-55.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$259M
Operating margin
-59.2%
Net margin
-21.0%
EPS (TTM, diluted)
$-0.73

Growth

Revenue growth
+8.9%
Change in growth rate
−1.7 pts
Share count change
+1.7%

Cash

Free cash flow (TTM)
-$130M
FCF margin
-50.3%
Stock pay % of revenue
14.9%

Earnings

Last results
August 5, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Schrodinger, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Schrodinger, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.38 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.8 ~$4.0–$5.3 Left out: out of range vs price (0.18x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.7 ~$7.9–$20 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$1.5 ~$1.5–$1.6 Left out: out of range vs price (0.06x)
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.7 ~$7.9–$20 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Schrodinger, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$79.18$34.83$18.69$35.80$19.29$17.88$26.19
Market value$4.8bn$2.5bn$1.3bn$2.7bn$1.4bn$1.3bn$1.9bn
+ Net debt (− = net cash)−$202m−$120m−$90m−$155m−$147m−$231m−$288m
Enterprise value$4.6bn$2.3bn$1.2bn$2.5bn$1.3bn$1.1bn$1.7bn
Multiples
Price / sales 44.0x17.8x7.4x12.4x6.8x5.1x7.5x
Price / earnings ———65.9x———
Price / free cash flow n/m————105.4x—
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

28 /100

Weak moat

How hard Schrodinger's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -2.4% of total assets over 6 years.

  • Pricing power 17 / 20

    Gross margin has been a median 58.3%, moving by 4.6 percentage points (standard deviation) across 7 years.

  • Durability 10 / 20

    Operating margin has been a median -79.3%; its worst year was -102.7%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 7 years, at a median -50.3% of revenue.

  • Discipline 4 / 20

    The diluted share count rose 7.3% over five years; stock-based pay has been a median 19.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (32 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $48m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.64 −17% $241m −6%
Next −$1.38 +16% $249m +3%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −18.0% on 90 days ago. In the last 30 days, 6 analysts raised Schrodinger, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Schrodinger, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.00 Current fiscal year, 60 days ago: −$1.60 Current fiscal year, 30 days ago: −$1.60 Current fiscal year, 7 days ago: −$1.64 Current fiscal year, Now: −$1.64 −$1.64 Next fiscal year, 90 days ago: −$1.22 Next fiscal year, 60 days ago: −$1.42 Next fiscal year, 30 days ago: −$1.42 Next fiscal year, 7 days ago: −$1.38 Next fiscal year, Now: −$1.38 −$1.38

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.00−$1.22
60 days ago −$1.60−$1.42
30 days ago −$1.60−$1.42
7 days ago −$1.64−$1.38
Now −$1.64−$1.38

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.67 −$0.42 +37.9%
Mar 2026 −$0.57 −$0.62 −8.9%
Dec 2025 −$0.09 −$0.18 −100.2%
Sept 2025 −$0.74 −$0.57 +23.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

7 analysts, Oct 2026
Buy571%
Hold229%
Sell00%

Monthly trend

  1. Oct 2026527
  2. Sep 2026527
  3. Aug 2026527
  4. Jul 2026527

Counts of recommendations published by analysts covering Schrodinger, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
24.8%
of tradable shares
Days to cover
3.16
at average volume
Short interest, 1 month
−7%
to October 15, 2026
Held by institutions
98%
of shares
Held by insiders
3.0%
of shares
Employees
850
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +24.5%

$21.04 on October 31, 2025 to $26.19

ThenNowEffect
Revenue (last 12 months) $238m $259m +8.9%
P/S multiple 6.5x 7.5x +16.2%
Share count 73m 74m −1.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −7.6%

$28.34 on November 3, 2023 to $26.19

ThenNowEffect
Revenue (last 12 months) $194m $259m +33.7%
P/S multiple 10.7x 7.5x −29.5%
Share count 73m 74m −1.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
SDGR−56%−46%+92%−46%−7%+47%
Industry peers (median)+5%−53%−3%−13%−2%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
SDGR25%42%67%25%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
SDGR−71%−55%−61%−53%−39%−41%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since February 6, 2020: 90% from March 1, 2021 to March 30, 2026. Getting back needed a 922% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$11.07 – $32.60
From 52-week high
−19.7%
vs 50-day average
+4.4%
vs 200-day average
+55.9%
Volatility (1 year)
66%
Beta vs S&P 500
1.75

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±8.2%
After a week
6 up, 6 down
typical move ±11.0%
After a month
6 up, 6 down
typical move ±14.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +13.8% −0.4% +19.0% +32.3%
May 5, 2026 +0.6% +2.2% −1.6% +22.9%
February 25, 2026 +12.9% +0.3% +16.1% +2.4%
November 5, 2025 −6.7% −0.7% −10.1% −11.8%
August 6, 2025 −1.4% +0.7% +1.0% −2.6%
May 7, 2025 +1.4% +1.1% +1.5% +4.5%
February 26, 2025 +5.7% −1.5% +3.8% −3.8%
November 12, 2024 +13.1% −0.3% −3.1% +7.8%
July 31, 2024 +0.1% +0.2% −20.0% −6.1%
May 1, 2024 −4.9% +0.6% −4.8% −11.7%
February 28, 2024 −23.1% +0.2% −25.0% −18.4%
November 1, 2023 +15.3% +3.0% +25.4% +49.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Schrodinger, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Schrodinger, Inc.
$180M $200M $220M $240M $260M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $199.4M Revenue (TTM), FY23 Q4: $216.7M Revenue (TTM), FY24 Q1: $188.5M Revenue (TTM), FY24 Q2: $200.6M Revenue (TTM), FY24 Q3: $193.3M Revenue (TTM), FY24 Q4: $207.5M Revenue (TTM), FY25 Q1: $230.5M Revenue (TTM), FY25 Q2: $237.9M Revenue (TTM), FY25 Q3: $257M Revenue (TTM), FY25 Q4: $255.9M Revenue (TTM), FY26 Q1: $254.9M Revenue (TTM), FY26 Q2: $259M $259M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $199.4M
FY23 Q4 $216.7M
FY24 Q1 $188.5M
FY24 Q2 $200.6M
FY24 Q3 $193.3M
FY24 Q4 $207.5M
FY25 Q1 $230.5M
FY25 Q2 $237.9M
FY25 Q3 $257M
FY25 Q4 $255.9M
FY26 Q1 $254.9M
FY26 Q2 $259M
Revenue growth, TTM YoY Schrodinger, Inc.
-10% 0% 10% 20% 30% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 17.1% Revenue growth, TTM YoY, FY23 Q4: 19.7% Revenue growth, TTM YoY, FY24 Q1: -4.4% Revenue growth, TTM YoY, FY24 Q2: 3.5% Revenue growth, TTM YoY, FY24 Q3: -3.0% Revenue growth, TTM YoY, FY24 Q4: -4.2% Revenue growth, TTM YoY, FY25 Q1: 22.3% Revenue growth, TTM YoY, FY25 Q2: 18.6% Revenue growth, TTM YoY, FY25 Q3: 32.9% Revenue growth, TTM YoY, FY25 Q4: 23.3% Revenue growth, TTM YoY, FY26 Q1: 10.6% Revenue growth, TTM YoY, FY26 Q2: 8.9% 8.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 17.1%
FY23 Q4 19.7%
FY24 Q1 -4.4%
FY24 Q2 3.5%
FY24 Q3 -3.0%
FY24 Q4 -4.2%
FY25 Q1 22.3%
FY25 Q2 18.6%
FY25 Q3 32.9%
FY25 Q4 23.3%
FY26 Q1 10.6%
FY26 Q2 8.9%
Operating margin (TTM) Schrodinger, Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -88.5% Operating margin (TTM), FY23 Q4: -81.9% Operating margin (TTM), FY24 Q1: -113.7% Operating margin (TTM), FY24 Q2: -102.7% Operating margin (TTM), FY24 Q3: -112.9% Operating margin (TTM), FY24 Q4: -100.8% Operating margin (TTM), FY25 Q1: -83.6% Operating margin (TTM), FY25 Q2: -81.1% Operating margin (TTM), FY25 Q3: -66.3% Operating margin (TTM), FY25 Q4: -65.2% Operating margin (TTM), FY26 Q1: -64.7% Operating margin (TTM), FY26 Q2: -59.2% -59.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -88.5%
FY23 Q4 -81.9%
FY24 Q1 -113.7%
FY24 Q2 -102.7%
FY24 Q3 -112.9%
FY24 Q4 -100.8%
FY25 Q1 -83.6%
FY25 Q2 -81.1%
FY25 Q3 -66.3%
FY25 Q4 -65.2%
FY26 Q1 -64.7%
FY26 Q2 -59.2%
FCF margin (TTM) Schrodinger, Inc.
-100% -50% 0% 50% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -68.6% FCF margin (TTM), FY23 Q4: -69.3% FCF margin (TTM), FY24 Q1: -84.3% FCF margin (TTM), FY24 Q2: -96.0% FCF margin (TTM), FY24 Q3: -89.2% FCF margin (TTM), FY24 Q4: -79.3% FCF margin (TTM), FY25 Q1: 9.6% FCF margin (TTM), FY25 Q2: 10.2% FCF margin (TTM), FY25 Q3: -1.3% FCF margin (TTM), FY25 Q4: 4.9% FCF margin (TTM), FY26 Q1: -58.2% FCF margin (TTM), FY26 Q2: -50.3% -50.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -68.6%
FY23 Q4 -69.3%
FY24 Q1 -84.3%
FY24 Q2 -96.0%
FY24 Q3 -89.2%
FY24 Q4 -79.3%
FY25 Q1 9.6%
FY25 Q2 10.2%
FY25 Q3 -1.3%
FY25 Q4 4.9%
FY26 Q1 -58.2%
FY26 Q2 -50.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 86 108 138 181 217 208 256 259
Gross profit 49 63 66 101 141 132 143 147
EBITDA −35 −57 −109 −142 −172 −203 −161 −148
Operating income −39 −61 −111 −147 −177 −209 −167 −153
Net income −25 −24 −100 −149 41 −187 −103 −54
Diluted EPS −$0.41 −$0.41 −$1.42 −$2.10 $0.54 −$2.57 −$1.41 −$0.73
Growth (year on year)
Revenue — +26.4% +27.6% +31.2% +19.7% −4.2% +23.3% +8.9%
Net income — — — — — −559.5% — —
Diluted EPS — — — — — −575.9% — —
Margins
Gross margin 57.4% 58.7% 47.6% 55.8% 64.9% 63.6% 55.7% 56.9%
EBITDA margin −41.0% −53.0% −78.7% −78.7% −79.3% −97.9% −62.9% −57.0%
Operating margin −45.3% −56.4% −80.8% −81.1% −81.9% −100.8% −65.2% −59.2%
Net margin −28.7% −22.6% −72.8% −82.4% 18.8% −90.2% −40.4% −21.0%
Free-cash-flow margin −32.6% 13.2% −56.4% −70.6% −69.3% −79.3% 4.9% −50.3%
Cash flow
Cash from operations −26 17 −71 −120 −137 −157 14 −127
Capital spending 2 3 7 8 13 7 1 3
Free cash flow −28 14 −78 −128 −150 −165 12 −130
Stock-based pay 2 11 26 40 48 50 43 39
Free cash flow after stock pay −30 4 −104 −167 −198 −215 −31 −169
Balance sheet
Cash 26 202 120 90 155 147 231 288
Total debt 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −26 −202 −120 −90 −155 −147 −231 −288
Diluted shares 60m 60m 71m 71m 75m 73m 73m 74m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $640m
Short-term assets $470mLonger-term assets $170m
What it owes, and who funded it · $640m
Short-term liabilities $174mLonger-term liabilities $138mShareholders' equity $329m
  • Short-term assets cover short-term liabilities $470m of assets due within a year against $174m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $470m short-term assets against $138m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Schrodinger, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.7%
year over year
R&D spending
65.2%
of revenue
Days sales outstanding
30 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated SDGR MLAB MRVI FLGT CTKB CSTL Median
Revenue, last 12 months $259m $250m $209m $324m $207m $357m $229m
Revenue growth, last 12 months 8.9% 3.0% −5.0% 6.8% 5.4% 3.2% 6.9%
Revenue growth, 3-year average 10.2% 4.4% −27.3% 1.8% 5.6% 28.7% 2.9%
Revenue growth, latest quarter 7.5% 1.0% 8.5% 4.4% 5.6% 20.1% 8.5%
Gross margin 56.9% 64.2% 34.9% 35.6% 53.2% 77.3% 51.9%
Operating margin −59.2% 9.0% −56.1% −37.7% −21.6% −9.0% −14.3%
Operating margin, 3-year average −81.0% −34.7% −73.7% −42.5% −16.1% −7.0% −22.4%
Net margin −21.0% 1.9% −37.1% −26.0% −39.0% −5.4% −16.1%
Cash from operations / revenue −49.0% 22.3% −12.1% −25.8% −2.9% 11.9% 1.3%
Free-cash-flow margin −50.3% 21.2% −17.2% −32.0% −5.9% −0.1% −2.2%
Free-cash-flow margin, 3-year average −45.4% 17.9% −14.3% −15.9% 1.7% 5.6% 0.6%
Stock pay / revenue 14.9% 6.5% 14.3% 11.6% 10.3% 12.6% 4.4%
Change in share count 1.7% 3.0% 2.3% −1.5% −0.3% −0.7% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 8.9% 6.9% 22 of 54
Change in growth rate Growth -1.7pp +0.4pp 40 of 54
Gross margin Profitability 56.9% 52.0% 17 of 45
Operating margin Profitability -59.2% -14.3% 37 of 52
Net margin Profitability -21.0% -12.2% 30 of 54
Free-cash-flow margin Cash generation -50.3% -1.3% 42 of 54
Stock pay as % of revenue Cash generation 14.9% 4.4% 41 of 53
Change in share count Balance sheet 1.7% 1.0% 27 of 46
Days sales outstanding Balance sheet 30 days 62 days 6 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Software $200M 78.0% ▲ 10.6%
Drug Discovery $56.4M 22.0% ▲ 107.4%
Products and services
Line of business Revenue YoY
Software Products and Services $200M ▲ 10.6%
Revenue From Contract With Customer Before Software Contribution $184M ▲ 6.5%
On Premise Software $101M ▼ 2.5%
Drug Discovery $56.4M ▲ 107.4%
Drug Discovery Services $54.8M ▲ 117.8%
Hosted Software $45.1M ▲ 28.0%
Maintenance $27.3M ▲ 17.2%
Professional Services $9.6M ▼ 1.5%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
United States $153M 59.8% ▲ 33.2%
EMEA $75.2M 29.4% ▲ 14.5%
APAC $26.2M 10.2% ▲ 1.5%
Outside the US $1.6M 0.6% ▲ 28.2%

From Schrodinger, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.1B
Institutions reporting
230
Shares held vs prior quarter
▼ 1.7%
Positions opened / closed
44 / 37

Top buyers and sellers, Q2 2026: 125 institutions bought and 100 sold ; the biggest buyer was AQR Capital Management LLC (+1.5M shares) and the biggest seller Massachusetts Financial Services Co (−1.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $171M 10.5M 16.3% ▲ 8.7%
Gates Foundation Trust $113M 7.0M 10.8% 0.0%
Rubric Capital Management LP $104M 6.4M 9.9% ▲ 6.7%
Vanguard Portfolio Management LLC $61.5M 3.8M 5.9% ▼ 1.9%
Sumitomo Mitsui Trust Group, Inc. $44M 2.7M 4.2% ▼ 15.2%
Amova Asset Management Americas, Inc. $43.9M 2.7M 4.2% ▼ 15.2%
Vanguard Capital Management LLC $43.7M 2.7M 4.2% ▲ 3.3%
State Street Corp $37.3M 2.3M 3.6% ▲ 4.9%
UBS Am, A Distinct Business Unit Of UBS Asset Management Americas LLC $36.1M 2.2M 3.4% ▼ 16.5%
ARK Investment Management LLC $35M 2.2M 3.3% ▲ 4.2%
AQR Capital Management LLC $31.8M 2.0M 3.0% ▲ 340.5%
Geode Capital Management, LLC $23.9M 1.5M 2.3% ▲ 8.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Schrodinger, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $2.3M 20 trades by 7 insiders · 100% under pre-set plans
Net ▼ $2.3M net selling
Insider Date Trade Shares Price Value
Akinsanya Karen See Remarks September 17, 2026 Sell pre-set plan 21,599 $30.00 $647,970
Akinsanya Karen See Remarks September 17, 2026 Sell pre-set plan 10,000 $28.00 $280,000
Jain Rachit EVP & CFO July 16, 2026 Sell pre-set plan 875 $15.60 $13,650
Farid Ramy President & CEO April 17, 2026 Sell pre-set plan 43,000 $12.21 $525,030
Jain Rachit EVP & CFO April 16, 2026 Sell pre-set plan 844 $12.75 $10,761
Farid Ramy President & CEO April 16, 2026 Sell pre-set plan 43,000 $12.33 $530,190
Herman Jenny CAO March 6, 2026 Sell pre-set plan 608 $12.84 $7,807
Lorton Kenneth Patrick EVP, CTO & COO, Software March 5, 2026 Sell pre-set plan 1,222 $12.90 $15,764
Akinsanya Karen See Remarks March 5, 2026 Sell pre-set plan 1,366 $12.90 $17,621
Farid Ramy President & CEO March 5, 2026 Sell pre-set plan 3,661 $12.91 $47,264
Tran Yvonne EVP, CLO & CPO March 5, 2026 Sell pre-set plan 1,094 $12.90 $14,113
Jain Rachit EVP & CFO March 5, 2026 Sell pre-set plan 1,631 $12.90 $21,040

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 5, 2026
  • February 25, 2026
  • November 5, 2025
  • August 6, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Schrodinger, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Schrodinger, Inc. in brief

What does Schrodinger, Inc. do?
Schrodinger, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Schrodinger, Inc.'s stock ticker?
Schrodinger, Inc. trades under the ticker SDGR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Schrodinger, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Schrodinger, Inc. reported revenue of $259M, 8.9% higher than a year earlier, according to its SEC filings.
What is Schrodinger, Inc.'s free cash flow?
Schrodinger, Inc.'s free-cash-flow margin is -50.3% of revenue over the trailing twelve months, ranking 42 of the 54 life sciences tools & services companies we cover.
Who are Schrodinger, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Gates Foundation Trust and Rubric Capital Management LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Schrodinger, Inc.'s market cap?
On November 2, 2026, Schrodinger, Inc.'s market capitalisation was about $1.9B and net debt of -$288M. Market figures come from third-party market data and may be delayed.
Who are Schrodinger, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Schrodinger, Inc. are Mesa Laboratories Inc, Maravai Lifesciences Holdings, Inc., Fulgent Genetics, Inc., Cytek Biosciences, Inc. and Castle Biosciences Inc. The side-by-side comparison below sets their revenue, margins and growth against Schrodinger, Inc.'s.
Are insiders buying or selling Schrodinger, Inc. stock?
Over the last 12 months, Schrodinger, Inc.'s directors and officers reported 0 open-market purchases and 20 sales on Form 4. The insider trading page charts every trade.
When is Schrodinger, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Schrodinger, Inc. announces its own schedule.